A Phase II Study of Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD) Combined With Everolimus in Patients With Recurrent or Metastatic ER-Positive (ER+) Endometrial Cancer (ELAVERA)

This phase II trial tests how well elacestrant with everolimus works for the treatment of estrogen receptor (ER) positive endometrial cancer that has come back after a period of improvement (recurrent), that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). Estrogen can cause the growth of cancer cells. Elacestrant lowers the amount of estrogen made by the body. This may help stop the growth of cancer cells that need estrogen to grow. Everolimus is in a class of medications called kinase inhibitors. It is also a type of angiogenesis inhibitor. Everolimus works by stopping cancer cells from reproducing and by decreasing blood supply to the cancer cells. Giving elacestrant with everolimus may be effective for treating patients with recurrent, advanced or metastatic ER positive endometrial cancer.

开始日期2026-12-18

申办/合作机构

Jonsson Comprehensive Cancer Center

[+1]

NCT07563595

/ RecruitingN/A

Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer: a Multicenter, National, Prospective Non-interventional Study

The objective of this non-interventional study (NIS) is to evaluate prevalence of ESR1 mutation after endocrine therapy in the palliative setting, quality of life, tolerability, and safety and to describe treatment detail and adverse event (AE) management in postmenopausal women with locally advanced and/or metastatic ER+ HER2- ESR1-mutated breast cancer and second line treatment with elacestrant according to SmPC (Summary of product characteristics) in a real-world setting.

开始日期2026-06-19

申办/合作机构

IOMEDICO AG

[+1]

CTIS2025-523460-21-00

/ Not yet recruiting临床2期IIT

A multicenter, multicohort, phase 2 platform trial to personalize second-line treatment intensity and targeting in HR-positive, HER2-negative metastatic breast cancer through an integrated liquid biopsy algorithm.

开始日期2026-06-01

申办/合作机构-

100 项与艾拉司群相关的临床结果

登录后查看更多信息

100 项与艾拉司群相关的转化医学

登录后查看更多信息

100 项与艾拉司群相关的专利（医药）

登录后查看更多信息

110

项与艾拉司群相关的文献（医药）

2026-06-13·EXPERT OPINION ON PHARMACOTHERAPY

Oral selective estrogen receptor degraders (SERDs) for the treatment of hormone receptor-positive, HER2-negative breast cancer title

Review

作者: Ferraro, Emanuela ; Minchella, Ida ; Berton Giachetti, Pier Paolo Maria ; Valenza, Carmine ; Marra, Antonio ; Crimini, Edoardo ; Zagami, Paola ; Trapani, Dario ; Etessami, Julian David ; Curigliano, Giuseppe ; Belli, Carmen

INTRODUCTION:

Endocrine therapy (ET) remains the backbone of treatment for hormone receptor-positive (HR+), HER2-negative breast cancer. However, resistance, frequently driven by acquired ESR1 mutations detected in up to 40% of patients progressing on first-line ET, represents a major clinical challenge. Oral selective estrogen receptor degraders (SERDs) have been developed to overcome the limitations of first-generation agents and achieve more potent ER targeting.

AREAS COVERED:

This review summarizes the mechanism of action of oral SERDs compared with prior endocrine therapies and evaluates clinical evidence supporting their use across treatment settings in HR+/HER2- breast cancer. Literature was identified through systematic searches of PubMed, ClinicalTrials.gov, and major oncology congresses (ASCO, ESMO, SABCS) through early 2026.

EXPERT OPINION:

Oral SERDs are reshaping the management of ESR1-mutant disease, with agents such as elacestrant and imlunestrant emerging as standard second-line options. In early-stage disease, trials such as lidERA suggest potential outcome improvements. However, primary resistance to SERD monotherapy remains substantial, highlighting the need for combination strategies. Future directions include ctDNA-guided approaches and expansion into earlier treatment settings.

2026-06-03·Expert Review of Anticancer Therapy

Elacestrant in metastatic breast cancer: current advancements and future perspectives

Review

作者: Aksoy, Sercan ; Sahin, Taha Koray ; Rizzo, Alessandro ; Guven, Deniz Can ; Di Lauro, Vincenzo ; Makasheva, Binura

INTRODUCTION:

Hormone receptor-positive and HER2-negative advanced breast cancer is the most prevalent subtype and poses therapeutic challenges. While endocrine therapy remains the cornerstone of management, acquired resistance, particularly stemming from ESR1 mutations, limits long-term efficacy. Consequently, novel endocrine agents with enhanced potency, oral bioavailability, and favorable tolerability are crucial for overcoming resistance and improving patient outcomes.

AREAS COVERED:

This review provides a comprehensive evaluation of elacestrant, an orally active selective estrogen receptor degrader that has transformed the treatment paradigm for endocrine resistant disease. The pharmacologic properties, antitumor activity, and clinical outcomes associated with elacestrant are discussed in detail, along with ongoing research exploring its integration into combination regimens and in earlier disease settings.

EXPERT OPINION:

Elacestrant has become an important therapeutic option for patients with ESR1-mutated disease, offering durable estrogen receptor suppression and favorable tolerability. Combination therapies targeting CDK4/6 and PI3K-AKT-TOR signaling pathways represent promising directions for extending endocrine sensitivity. With the growing integration of liquid biopsy technologies and molecular monitoring into clinical practice, dynamic treatment adaptation guided by real time molecular profiling is expected to refine therapy selection. Elacestrant is a benchmark in the shift toward individualized endocrine therapy in metastatic breast cancer, bridging molecular precision with clinical practicality.

2026-04-01·CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Real-world evidence for 10 oncology drugs approved in the last 5 years: A comprehensive narrative synthesis

Review

作者: Oggionni, Emanuela ; Balconi, Elena ; Parati, Maria Chiara ; Rossitto, Mauro ; Petrò, Daniela ; Petrelli, Fausto ; Ghilardi, Mara ; Colombo Zefinetti, Lara ; Dottorini, Lorenzo ; Borgonovo, Karen ; Zambelli, Alberto ; Dognini, Giuseppina ; Castelli, Emanuela

IMPORTANCE:

Randomized controlled trials (RCTs) establish the efficacy of new oncology drugs but often exclude older adults, patients with comorbidities, and individuals with poorer performance status. Real-world evidence (RWE) is therefore essential to determine whether trial benefits translate to the broader populations treated in routine practice.

OBJECTIVE:

To synthesize contemporary RWE on the effectiveness and safety of ten oncology drugs approved between 2020 and 2025 for solid tumors, focusing on studies with ≥ 100 patients to maximize robustness and generalizability.

EVIDENCE REVIEW:

A systematic search of PubMed/MEDLINE, Embase, Scopus, Web of Science, and major conference proceedings (ASCO, ESMO, AACR) identified observational cohorts, registries, expanded-access programs, and claims-based studies published from January 2020 to January 2025.

FINDINGS:

Twenty studies (N > 3400) met inclusion criteria: breast cancer (9), lung cancer (7), urothelial carcinoma (3), and endometrial cancer (1). In breast cancer, sacituzumab govitecan reproduced ASCENT outcomes (ORR 27-30 %; PFS 4.8-5.2 months), trastuzumab deruxtecan achieved ORRs near 70 % in HER2-positive disease and median PFS 7.5 months in HER2-low cohorts, and elacestrant showed real-world time-to-next-treatment of 7.9-10.8 months in ESR1-mutant ER+ /HER2 - disease. In NSCLC, sotorasib and adagrasib demonstrated ORRs of ∼28-34 % and PFS 3.5-6 months, selpercatinib provided durable disease control, and MET inhibitors (capmatinib, tepotinib) yielded PFS around 6-7 months. In urothelial carcinoma, enfortumab vedotin produced ORRs of 31-73 % across datasets. In endometrial cancer, dostarlimab generated highly durable responses in dMMR/MSI-H disease.

CONCLUSIONS:

RWE confirms the effectiveness and safety of multiple recently approved oncology drugs reinforcing the external validity of RCTs.

397

项与艾拉司群相关的新闻（医药）

2026-07-20

·ioncology

ESMO 2026丨瞭望前瞻，百余项中国乳腺癌研究亮相ESMO，一文速览

点击蓝字，关注我们编者按：2026年欧洲肿瘤内科学会年会（ESMO 2026）将于10月23日至27日在西班牙马德里召开。作为全球肿瘤领域最具影响力的年度盛会之一，ESMO每年覆盖基础研究、转化医学与临床诊疗全维度前沿进展，是国际肿瘤学界交流学术成果、更新诊疗理念的核心平台。目前，ESMO官网已公布部分摘要标题，《肿瘤瞭望》特针对乳腺癌领域的中国入选研究进行系统梳理，供读者提前把握本次大会的中国学术动态。（由于目前多数研究摘要全文尚未正式发布，本次整理仅基于已公开的标题信息，如有疏漏或表述偏差，敬请留言指正。）快速口头报告摘要号：4RO 英文标题：Target switching with conserved-payload novel ADCs in patients with metastatic breast cancer following prior ADC therapy (SWITCH): a prospective, open-label, phase 2 platform trial 中文标题：转移性乳腺癌ADC经治后采用同载荷异载荷新型ADC的靶点转换研究：一项前瞻性、开放标签的 II 期平台试验（SWITCH）讲者：刘西禹 (复旦大学附属肿瘤医院) 摘要号：5RO 英文标题：Safety and efficacy of SYS6043, a Novel B7-H3–Targeting Antibody-Drug Conjugate, in Patients with Advanced breast cancer 中文标题：新型靶向B7-H3 ADC SYS6043治疗晚期乳腺癌的安全性与有效性讲者：王红霞 (复旦大学附属肿瘤医院) 摘要号：4639RO 英文标题：Final OS analysis of sacituzumab tirumotecan versus chemotherapy in previously treated locally recurrent or metastatic triple-negative breast cancer: Phase III OptiTROP-Breast01 中文标题：芦康沙妥珠单抗对比化疗用于既往经治局部复发或转移性三阴性乳腺癌的III期OptiTROP-Breast01研究最终OS分析讲者：樊英 (中国医学科学院肿瘤医院) 摘要号：4640RO 英文标题：Bulumtatug Fuvedotin (BFv, 9MW2821), a Nectin-4–Directed Antibody-Drug Conjugate (ADC), in Patients with Locally Advanced or Metastatic Triple Negative Breast Cancer (la/mTNBC) Previously Treated with Topoisomerase I Inhibitor (TopI)-Based ADCs: Results from a Phase 2 Study 中文标题：新型靶向Nectin-4 ADC bulumtatug Fuvedotin（BFv，9MW2821）在既往接受过拓扑异构酶I抑制剂为基础的ADC治疗的局部晚期或转移性三阴性乳腺癌（la/mTNBC）患者中显示出显著疗效：一项II期临床研究的结果讲者：张剑 (复旦大学附属肿瘤医院) 壁报 Basic science（基础科学）摘要号：399P 英文标题：C15orf48 drives breast cancer liver metastasis via glutathione dependent activation of Wnt/β-catenin signaling 中文标题：C15orf48通过谷胱甘肽依赖性激活Wnt/β-catenin信号通路驱动乳腺癌肝转移讲者：宋振川（河北医科大学第四医院） Advanced breast cancer, other（晚期乳腺癌，其他）摘要号：6P 英文标题：Machine learning model based on pathomics features predicts T-DXd response in advanced breast cancer 中文标题：基于病理组学特征的机器学习模型可预测晚期乳腺癌对T-DXd治疗的反应讲者：刘月平（河北医科大学第四医院）摘要号：10P 英文标题：A randomized phase 3 study of disitamab vedotin (DV) versus chemotherapy (chemo) in HER2-low advanced breast cancer: overall and the liver metastasis (BCLM) subgroup results 中文标题：维迪西妥单抗对比化疗治疗HER2低表达晚期乳腺癌的随机III期研究：总体及肝转移亚组结果讲者：王佳玉（中国医学科学院肿瘤医院）摘要号：19P 英文标题：Ribociclib plus endocrine therapy versus chemotherapy in patients with rapidly progressive HR+/HER2− advanced breast cancer: a multicenter phase II study with external controls 中文标题：瑞波西利联合内分泌治疗对比化疗用于快速进展HR+/HER2−晚期乳腺癌：一项多中心II期研究及外部对照讲者：Min Tian (Nanjing, China) 摘要号：26P 英文标题：Efficacy and Safety of Anlotinib-Based Therapy in Advanced Breast Cancer: A Real-World Study 中文标题：以安罗替尼为基础方案治疗晚期乳腺癌的真实世界疗效与安全性研究讲者：姚静（华中科技大学同济医学院附属协和医院）摘要号：27P 英文标题：Local treatment in metastatic breast cancer with oligoprogression: a retrospective cohort study and reconstructive individual patient data meta-analysis 中文标题：寡进展转移性乳腺癌的局部治疗：回顾性队列研究与重建个体患者数据荟萃分析讲者：Haoting Shi (Shanghai, China) 摘要号：73eP 英文标题：Chidamide combined with Vinorelbine and Capecitabine for HER2-Negative Advanced Breast Cancer: A Single-Arm, Single-Center, Phase II Clinical Trial 中文标题：西达本胺联合长春瑞滨和卡培他滨治疗HER2阴性晚期乳腺癌：一项单臂、单中心II期临床试验讲者：La Zou (Chongqing, China) 摘要号：74eP 英文标题：Intraventricular thiotepa in combination with methotrexate for leptomeningeal metastasis from breast cancer (NJMU-BC04): a single-arm phase II study 中文标题：脑室内注射塞替哌联合甲氨蝶呤治疗乳腺癌软脑膜转移（NJMU-BC04）：一项单臂II期研究讲者：Mengyao Zha (Nanjing, China) 摘要号：79eP 英文标题：Eribulin After Antibody-Drug Conjugate Treatment in Metastatic Breast Cancer: A Real-World Multicenter Retrospective Study 中文标题：抗体偶联药物治疗后应用艾立布林治疗转移性乳腺癌：一项真实世界多中心回顾性研究讲者：邵彬（北京大学肿瘤医院）摘要号：83eP 英文标题：An EGFR dominating triple positive tumor clone engages cycling M2 macrophages during disease progression following bispecific HER3/EGFR antibody-drug conjugate (ADC) treatment in metastatic breast cancer 中文标题：EGFR主导的三阳性肿瘤克隆在转移性乳腺癌双特异性HER3/EGFR ADC治疗后疾病进展中招募循环M2巨噬细胞讲者：吕铮（吉林大学第一医院）摘要号：96eP 英文标题：Real-world effectiveness of antibody-drug conjugates versus conventional systemic therapies in metastatic breast cancer: An inverse probability of treatment weighting analysis 抗体偶联药物对比传统全身治疗在转移性乳腺癌中的真实世界疗效：逆概率处理加权分析讲者：Shukai Guo (Fuzhou, China) Breast cancer, early stage（早期乳腺癌）摘要号：547P 英文标题：Predictive Role of ctDNA for Pseudoprogression in Triple-Negative Breast Cancer during Neoadjuvant Immunotherapy 中文标题：ctDNA在三阴性乳腺癌新辅助免疫治疗期间假性进展的预测作用讲者：王永胜（山东省肿瘤医院）摘要号：560P 英文标题：Efficacy and Safety of Pyrotinib Combined with Trastuzumab and Aromatase Inhibitor in Neoadjuvant Treatment of HER2+/HR+ Breast Cancer: A Single-Arm, Multi-Center Phase II Exploratory Study 中文标题：吡咯替尼联合曲妥珠单抗和芳香化酶抑制剂新辅助治疗HR+/HER2+乳腺癌：一项单臂、多中心II期探索性研究讲者：葛洁（天津医科大学肿瘤医院）摘要号：570P 英文标题：Qualitative synergism between female hormone use and secondhand smoke on breast carcinogenesis: A prospective cohort study 中文标题：雌激素使用与二手烟在乳腺癌发生中的定性协同作用：一项前瞻性队列研究讲者：Hong-Hong Zhu (Quzhou, China) 摘要号：580P 英文标题：Ki-67-Guided Stratification and Resistance Mechanism Analysis of CDK4/6 Inhibitor Therapy Following Adaptive Neoadjuvant Endocrine Treatment in HR+/HER2− Breast Cancer 中文标题：HR+/HER2-乳腺癌中适应性新辅助内分泌治疗后CDK4/6抑制剂治疗的Ki-67引导分层与耐药机制分析讲者：王永胜（山东省肿瘤医院）摘要号：616eP 英文标题：Radiotherapy-Integrated Neoadjuvant Therapy Deepens Response and Expands Eligibility for Surgery Omission in TNBC and HR-/HER2+ Breast Cancer: Interim Analysis of a Multicenter Phase II Study 中文标题：放疗联合新辅助治疗可增强对TNBC和HR-/HER2+乳腺癌的疗效，并扩大免手术治疗发适应证：一项多中心II期研究期中分析讲者：杨正军（天津医科大学肿瘤医院）摘要号：617eP 英文标题：Ultrasound-Guided Vacuum-Assisted Excision Followed by Definitive Surgery in Early-Stage Small Breast Cancer: A Single-Arm Trial 中文标题：超声引导下真空辅助旋切术后续根治性手术治疗早期小乳腺癌：一项单臂试验讲者：Siyuan Wang (Xi'an, China) 摘要号：628eP 英文标题：Extended Sentinel Lymph Node Biopsy Using a Single Tracer After Neoadjuvant Therapy for Breast Cancer: A Retrospective Real-World Study 中文标题：乳腺癌新辅助治疗后应用单一示踪剂的扩展前哨淋巴结活检：一项回顾性真实世界研究讲者：张聚良（空军军医大学西京医院）摘要号：635eP 英文标题：Profound Vitamin D Deficiency Identifies Elevated Heart Failure Risk Among Breast Cancer Survivors: A UK Biobank Multi-State Analysis 中文标题：重度维生素D缺乏识别乳腺癌幸存者中升高的心力衰竭风险：一项UK Biobank多状态分析讲者：Yiyin Zhang (Beijing, China) 摘要号：636eP 英文标题：A novel single-molecule dual CDK4/CDK2 inhibitor series with cytotoxic cellular activity and improved kinome selectivity for HR+/HER2− breast cancer and CCNE1-amplified ovarian cancer 中文标题：新型单分子双靶点CDK4/CDK2抑制剂系列：针对HR+/HER2−乳腺癌和CCNE1扩增卵巢癌具有细胞毒活性和改善的激酶组选择性讲者：Xianqiang Sun (Shanghai, China) 摘要号：639eP 英文标题：Carbon Nano-Lymph Tracer in Modified Radical Mastectomy After Neoadjuvant Chemotherapy for Breast Cancer 中文标题：纳米碳淋巴示踪剂在乳腺癌新辅助化疗后改良根治术中的应用讲者：Feng Liu (Fuyang, China, Anhui) 摘要号：646eP 英文标题：Patient and Oncologist Preferences Regarding CDK4/6 Inhibitor Adjuvant Therapy for HR+/HER2- Early Breast Cancer in China 中文标题：中国HR+/HER2−早期乳腺癌患者与肿瘤科医生对CDK4/6抑制剂辅助治疗的偏好讲者：郝春芳（天津医科大学肿瘤医院）摘要号：648eP 英文标题：Standard imaging-guided, Doppler-free chest wall perforator flap reconstruction for granulomatous lobular mastitis: A simplified approach for resource-limited settings 中文标题：标准影像引导下，无多普勒胸壁穿支皮瓣重建术治疗肉芽肿性小叶性乳腺炎：面向资源有限地区的简化方案讲者：王子莹（常州市第一人民医院） HER2+ breast cancer（HER2阳性乳腺癌）摘要号：1772P 英文标题：A Study Evaluating the Safety and Efficacy of Pyrotinib Dose Escalation Plus Loperamide Prophylaxis in First-Line Treatment of Advanced HER2-Positive Breast Cancer 中文标题：一项评估吡咯替尼剂量递增联合洛哌丁胺预防HER2阳性晚期乳腺癌一线治疗中安全性与有效性的研究讲者：晁腾飞（华中科技大学同济医学院附属同济医院）摘要号：1773P 英文标题：Neoadjuvant Oral Paclitaxel Plus Subcutaneous Fixed-Dose Pertuzumab/Trastuzumab in Stage II-III HER2+ Breast Cancer: First-Stage Results from a Simon's Two-Stage Study 中文标题：口服紫杉醇联合皮下注射固定剂量帕妥珠单抗/曲妥珠单抗新辅助治疗II-III期HER2+乳腺癌：Simon两阶段设计第一阶段结果讲者：Yudong Li (Guangzhou, China) 摘要号：1775P 英文标题：Dalpiciclib plus Pyrotinib-Based Chemotherapy-Free Regimens as first line treatment in Trastuzumab-Sensitive, HER2-Positive Metastatic Breast Cancer (DAP-HER-02): A Dual-Cohort, Phase II Study 中文标题：达尔西利联合吡咯替尼无化疗方案一线治疗曲妥珠单抗敏感的HER2阳性转移性乳腺癌（DAP-HER-02）：一项双队列II期研究讲者：牛李敏（郑州大学第一附属医院）摘要号：1776P 英文标题：IBI354 plus pertuzumab as first-line (1L) treatment for patients with HER2-positive, unresectable locally advanced or metastatic breast cancer: Results from a phase 2 study 中文标题：IBI354联合帕妥珠单抗一线治疗HER2阳性不可切除局部晚期或转移性乳腺癌：一项II期研究结果讲者：曾晓华（重庆大学附属肿瘤医院）摘要号：1778P 英文标题：Updated results of SHR-A1811 plus pertuzumab in human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic breast cancer: a phase 1b/2 study 中文标题：SHR-A1811联合帕妥珠单抗治疗HER2阳性不可切除/转移性乳腺癌的更新结果：一项Ib/II期研究讲者：黄香（南京医科大学第一附属医院）摘要号：1779P 英文标题：Prognostic Impact of PIK3CA Mutations in HER2-Positive Advanced Breast Cancer: A Real-World Multicenter Study 中文标题：PIK3CA突变对HER2阳性晚期乳腺癌的预后影响：一项真实世界多中心研究讲者：王瓯晨（温州医科大学附属第一医院）摘要号：1781P 英文标题：Real-World Comparative Study of Pertuzumab- vs Pyrotinib-Based First-Line Regimens in HER2-Positive Advanced Breast Cancer: A Xinjiang Multicenter Study 中文标题：帕妥珠单抗对比吡咯替尼一线治疗HER2阳性晚期乳腺癌的真实世界比较：一项新疆多中心研究讲者：赵兵（新疆医科大学附属肿瘤医院）摘要号：1802eP 英文标题：Neoadjuvant Chemotherapy plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer: A Prospective, Single-arm, Multi-center Study (NEOTORCH-BREAST05) 中文标题：新辅助化疗联合吡咯替尼和曲妥珠单抗治疗HER2阳性乳腺癌：一项前瞻性、单臂、多中心研究（NEOTORCH-BREAST05）讲者：Zhijun Dai (Hangzhou, China) 摘要号：1803eP 英文标题：Multicenter, phase II study of eribulin, carboplatin, trastuzumab and pertuzumab as neoadjuvant therapy in HER2-positive early or locally advanced breast cancer 中文标题：艾立布林、卡铂、曲妥珠单抗和帕妥珠单抗新辅助治疗HER2阳性早期或局部晚期乳腺癌的多中心II期研究讲者：Di Lu (Chengdu, China) 摘要号：1810eP 英文标题：Inetetamab Combined with Pyrotinib for HER2-Positive Advanced Breast Cancer: A Multicenter Real-World Retrospective Study 中文标题：伊尼妥单抗联合吡咯替尼治疗HER2阳性晚期乳腺癌：一项多中心真实世界回顾性研究讲者：Zenggui Wu (Taizhou, China) 摘要号：1812eP 英文标题：Enhanced protein lactylation accompanies acquired resistance to trastuzumab deruxtecan in HER2-positive breast cancer 中文标题：增强的蛋白乳酰化伴随HER2阳性乳腺癌对德曲妥珠单抗的获得性耐药讲者：Nan Jin (Nanjing, China) 摘要号：1814eP 英文标题：Antibody-programmable MOFs reshape multi-dimensional intervention strategies for programmed cell death in HER2+ breast cancer 中文标题：抗体可编程金属有机框架重塑HER2+乳腺癌程序性细胞死亡的多维干预策略讲者：王宇（首都医科大学附属北京同仁医院）摘要号：1818eP 英文标题：Characterization of Antibody Drug Conjugate-Associated Interstitial Lung Disease in Breast Cancer: A Systematic Review and Meta-Analysis 中文标题：乳腺癌抗体偶联药物相关间质性肺病的特征：系统综述与荟萃分析讲者：Yinuo Dong (Beijing, China) 摘要号：1823eP 英文标题：Ranking of First-Line Treatments for Advanced HER2-Positive Breast Cancer: A Bayesian Network Meta-Analysis 中文标题：HER2阳性晚期乳腺癌一线治疗的排序：贝叶斯网络荟萃分析讲者：Yuxin Sun (Beijing, China) 摘要号：1828eP 英文标题：Breast Ultrasound for Early Prediction of Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer: A Real-World Analysis 中文标题：乳腺超声用于HER2阳性乳腺癌新辅助治疗疗效早期预测的真实世界分析讲者：Yuhang Xiao (Nanjing, China) 摘要号：1838eP 英文标题：FAP Expression Heterogeneity Drives Efficacy Variation of Targeted Radioligand Therapy and Patient Selection in HER2-Positive Breast Cancer 中文标题：FAP表达异质性驱动HER2阳性乳腺癌靶向放射性配体治疗的疗效差异与患者筛选讲者：Ting Wu (Luzhou, China) 摘要号：1841eTiP 英文标题：Al18F-HER2-BCH PET/CT guided precision neoadjuvant therapy for HER2-positive early breast cancer: FHERNAT trial 中文标题：Al18F-HER2-BCH PET/CT引导的HER2阳性早期乳腺癌精准新辅助治疗：FHERNAT试验讲者：梁旭（北京大学肿瘤医院） HR+ breast cancer（激素受体阳性乳腺癌）摘要号：1847P 英文标题：SHR-A2102, a Nectin-4-directed antibody drug conjugate (ADC), in pretreated HR+/HER2- advanced breast cancer: results from a phase 1 study 中文标题：SHR-A2102（靶向Nectin-4的ADC）用于经治HR+/HER2−晚期乳腺癌：一项I期研究结果讲者：闫敏（郑州大学附属肿瘤医院）摘要号：1848P 英文标题：First-in-human study of JYP0035, a highly selective PI3Kα inhibitor, as monotherapy in patients with advanced solid tumors 中文标题：高选择性PI3Kα抑制剂JYP0035单药治疗晚期实体瘤的首次人体研究讲者：孟艳春（复旦大学附属肿瘤医院）摘要号：1849P 英文标题：A Phase 1b/2 Study of JS105 in Combination with Dalpiciclib and Fulvestrant in Patients with Advanced Breast Cancer 中文标题：JS105联合达尔西利和氟维司群治疗晚期乳腺癌的Ib/II期研究讲者：闫敏（郑州大学附属肿瘤医院）摘要号：1852P 英文标题：Evaluation of the safety and efficacy of SH3765 in combination with fulvestrant in HR+/HER2− advanced breast cancer: a phase Ib study 中文标题：SH3765联合氟维司群治疗HR+/HER2−晚期乳腺癌的安全性与疗效评估：一项Ib期研究讲者：潘跃银（中国科学技术大学附属第一医院）摘要号：1858P 英文标题：BL0175 Injection for Locally Advanced/Metastatic HR+/HER2− Breast Cancer: Preliminary Results from Dose Escalation Stage of a Phase 1 Study 中文标题：BL0175注射液治疗局部晚期/转移性HR+/HER2−乳腺癌：I期剂量递增阶段初步结果讲者：王楠娅（吉林大学第一医院）摘要号：1859P 英文标题：First-line fovinaciclib for advanced breast cancer: updated analysis of a randomized, double-blind phase 3 study 中文标题：伏维西利一线治疗晚期乳腺癌：随机双盲III期研究更新分析讲者：袁芃（中国医学科学院肿瘤医院）摘要号：1869P 英文标题：Lysine acetyltransferase 6A (KAT6A) for predicting tamoxifen resistance in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer 中文标题：赖氨酸乙酰转移酶6A预测HR+/HER2−早期乳腺癌他莫昔芬耐药讲者：Tan Yujing (Beijing, China) 摘要号：1881P 英文标题：Clinical outcomes of YL202/BNT326 (HER3 ADC) in advanced/metastatic HR+/HER2-null/low breast cancer in chemotherapy-naïve and exposed patients 中文标题：YL202/BNT326（HER3 ADC）在初治和经治晚期/转移性HR+/HER2零表达/低表达乳腺癌中的临床结局讲者：孟艳春（复旦大学附属肿瘤医院）摘要号：1886TiP 英文标题：A phase I/II study of GenSci145 as monotherapy or combination therapy in PIK3CA-mutated advanced solid tumors 中文标题：GenSci145单药或联合治疗PIK3CA突变晚期实体瘤的I/II期研究讲者：徐兵河（中国医学科学院肿瘤医院）摘要号：1890eP 英文标题：Integrated Molecular Profiling of Paired Tumor Tissue and Circulating Tumor DNA in Chinese Patients with HR+/HER2- Advanced Breast Cancer Prior to First-Line Systemic Therapy 中文标题：中国HR+/HER2−晚期乳腺癌患者一线全身治疗前配对肿瘤组织与循环肿瘤DNA的整合分子分型讲者：岳健（中国医学科学院肿瘤医院）摘要号：1892eP 英文标题：An Open-label, Single-arm Study of Dalpiciclib in Combination with Aromatase Inhibitor and Capecitabine as Neoadjuvant Therapy for high-risk HR+/HER2- Early Breast Cancer 中文标题：达尔西利联合芳香化酶抑制剂和卡培他滨新辅助治疗高危HR+/HER2−早期乳腺癌：一项开放标签、单臂研究讲者：韩忠华（福建医科大学附属协和医院）摘要号：1893eP 英文标题：Dalpiciclib combined with endocrine therapy and capecitabine in high-risk HR+/HER2- advanced breast cancer: a multicenter phase II study 中文标题：达尔西利联合内分泌治疗和卡培他滨治疗高危HR+/HER2−晚期乳腺癌：一项多中心II期研究讲者：张捷（福建医科大学附属协和医院）摘要号：1895eP 英文标题：Early Toxicity-Driven Dose Modification Preserves Efficacy of Adjuvant Abemaciclib in High-Risk HR+/HER2− Early Breast Cancer: A Real-World Study in Chinese Patients 中文标题：早期毒性驱动的剂量调整不影响高危HR+/HER2−早期乳腺癌辅助阿贝西利疗效：一项中国患者真实世界研究讲者：Jing Huang (Xi'an, China) 摘要号：1896eP 英文标题：Fruquintinib plus eribulin in patients with metastatic HR+, HER2- breast cancer after progression on endocrine therapy plus CDK4/6 inhibitor: Updated results from a phase II study 中文标题：呋喹替尼联合艾立布林治疗内分泌治疗联合CDK4/6抑制剂进展后的转移性HR+/HER2−乳腺癌：II期研究更新结果讲者：袁渊（南京医科大学第一附属医院）摘要号：1898eP 英文标题：Real-World Outcomes of First-Line CDK4/6 Inhibitors Plus Endocrine Therapy in HR+/HER2- Advanced Breast Cancer: A Large National Cohort Study in China 中文标题：CDK4/6抑制剂联合内分泌治疗一线治疗HR+/HER2−晚期乳腺癌的真实世界结局：中国大型全国性队列研究讲者：罗扬（中国医学科学院肿瘤医院）摘要号：1903eP 英文标题：Patient-reported outcomes after switching from goserelin implant to goserelin microsphere in breast cancer: preliminary results of a prospective study 中文标题：乳腺癌患者从戈舍瑞林植入剂转换为戈舍瑞林微球后的患者报告结局：一项前瞻性研究初步结果讲者：张蓝心（大连医科大学附属第二医院）摘要号：1904eP 英文标题：CPS-EG Combined With Postoperative Ki-67 Outperforms ypTNM for Prognostication in HR+/HER2- Breast Cancer After Neoadjuvant Therapy: An 801-Patient Single-Center Retrospective Cohort Study 中文标题：CPS-EG联合术后Ki-67对HR+/HER2−乳腺癌新辅助治疗后预后的预测价值优于ypTNM：一项801例患者单中心回顾性队列研究讲者：Tian Yi Zhou (Guangzhou, China) 摘要号：1907eP 英文标题：Real-World Effectiveness and Safety of the Novel Agent Inavolisib in Heavily Pretreated, PIK3CA-mut Advanced Breast Cancer: A Multicenter Study of Patients with More Advanced and Complex Disease 中文标题：伊那利塞在重度经治PIK3CA突变晚期乳腺癌中的真实世界疗效与安全性：一项针对病情更晚期复杂疾病患者的多中心研究讲者：梁旭（北京大学肿瘤医院）摘要号：1911eP 英文标题：Optimal sequencing of systemic therapies for HR+/HER2− advanced breast cancer stratified by visceral and liver metastases: a systematic review and network meta-analysis 中文标题：按内脏和肝转移分层HR+/HER2−晚期乳腺癌全身治疗的最佳序贯策略：系统综述与网络荟萃分析讲者：Hong Cheng (Beijing, China) 摘要号：1918eP 英文标题：ABC-RWS-01 interim analysis of elacestrant in Chinese ESR1-mutated ER+/HER2- advanced breast cancer 中文标题：Elacestrant治疗中国ESR1突变ER+/HER2−晚期乳腺癌的ABC-RWS-01研究期中分析讲者：Wenbo Shi (Qionghai, China) 摘要号：1923eP 英文标题：Real-World Effectiveness and Safety of Maintenance Endocrine Therapy With or Without CDK4/6 Inhibitors Following Chemotherapy in HR-Positive/HER2-Negative Advanced Breast Cancer 中文标题：HR+/HER2-晚期乳腺癌化疗后维持内分泌治疗联合或不联合CDK4/6抑制剂的真实世界疗效与安全性讲者：李慧慧（山东省肿瘤医院）摘要号：1929eP 英文标题：Characterization of PIK3CA variants and real-world clinical evolution of first-line CDK4/6 inhibitors: Insights from a Chinese HR+/HER2- advanced breast cancer cohort 中文标题：PIK3CA变异特征与一线CDK4/6抑制剂治疗的真实世界临床演变：来自中国HR+/HER2−晚期乳腺癌队列的见解讲者：石晶（中国医科大学附属第一医院）摘要号：1936eP 英文标题：Safety profile of exemestane vs. anastrozole in the real world: a disproportionality analysis of FAERS database and systematic review of case reports 中文标题：依西美坦对比阿那曲唑的真实世界安全性：FAERS数据库不相称性分析与病例报告系统综述讲者：Chunsu Liang (Beijing, China) 摘要号：1943eTiP 英文标题：SoGreat: A phase Ib modular study of sacituzumab govitecan plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer after progression on CDK4/6 inhibitors 中文标题：SoGreat：戈沙妥珠单抗联合内分泌治疗用于CDK4/6抑制剂进展后HR+/HER2-转移性乳腺癌的Ib期模块化研究讲者：Zhonghui Zheng (Shanghai, China) 摘要号：1944eTiP 英文标题：The NASA (Neoadjuvant Ribociclib plus Aromatase Inhibitor) Trial: A randomized comparison versus chemotherapy in HR+/HER2- EBC 中文标题：NASA试验（新辅助哌柏西利联合芳香化酶抑制剂）：HR+/HER2−早期乳腺癌中对比化疗的随机对照研究讲者：蔡子杰（中山大学孙逸仙纪念医院） Supportive care（支持治疗）摘要号：3950P 英文标题：Musculoskeletal pain, neutrophil recovery kinetics, and exploratory immune-profiling with telpegfilgrastim versus other long-acting G-CSFs in breast cancer: TELEGRAM 中文标题：乳腺癌中拓培非格司亭对比其他长效G-CSF的肌肉骨骼疼痛、中性粒细胞恢复动力学及探索性免疫分型：TELEGRAM研究讲者：李薇（南京医科大学第一附属医院）摘要号：4028eP 英文标题：Efficacy and safety of telpegfilgrastim in breast cancer patients undergoing (neo)adjuvant chemotherapy for prophylaxis of chemotherapy-induced neutropenia: A multicenter, prospective, observational study 中文标题：拓培非格司亭在乳腺癌（新）辅助化疗患者预防化疗所致中性粒细胞减少的疗效与安全性：一项多中心、前瞻性、观察性研究讲者：张少华（解放军总医院）摘要号：4057eP 英文标题：Prospective Cohort Study on the Prophylaxis of Catheter-related Thrombosis in Breast Cancer Patients 中文标题：乳腺癌患者导管相关血栓预防的前瞻性队列研究讲者：Shiyu Li (Beijing, China) 摘要号：4071eP 英文标题：Auricular point stimulation plus dexamethasone for nausea and vomiting caused by docetaxel combined with cyclophosphamide in breast cancer adjuvant chemotherapy (ADDC) 中文标题：耳穴刺激联合地塞米松用于乳腺癌辅助化疗多西他赛联合环磷酰胺所致恶心呕吐（ADDC研究）讲者：Juan Wang (Hangzhou, China) 摘要号：4138eP 英文标题：Physiological and Functional Responses to Ultrasound-Guided Dextrose Hydrodissection in Breast Cancer Survivors With Persistent Chest Wall and Axillary Tightness 中文标题：超声引导下葡萄糖水分离术对持续性胸壁和腋窝紧绷的乳腺癌幸存者的生理与功能反应讲者：Yuchun Lee（中国台湾台中市） Triple negative breast cancer（三阴性乳腺癌）摘要号：4651P 英文标题：Competing risk nomogram for cancer-specific mortality and risk-stratified treatment associations in women with T2N0M0 triple-negative breast cancer: a SEER study (2010-2016) 中文标题：T2N0M0三阴性乳腺癌患者癌症特异性死亡竞争风险列线图及风险分层治疗关联：一项SEER研究（2010-2016）讲者：Sirui Zhu (Beijing, China) 摘要号：4652P 英文标题：225Ac-PSMA-targeted alpha therapy (TRC003) in metastatic TNBC: A prospective, multicenter, single-arm safety/efficacy trial 中文标题：225Ac-PSMA靶向α核素治疗（TRC003）在转移性TNBC中的应用：一项前瞻性、多中心、单臂安全性与疗效试验讲者：孙晓蓉（山东第一医科大学附属肿瘤医院）摘要号：4653P 英文标题：A phase 2, multicenter, open-label study to evaluate the efficacy and safety of ATRA plus toripalimab and chemotherapy in patients with previously treated locally advanced or metastatic triple-negative breast cancer 中文标题：ATRA联合特瑞普利单抗和化疗治疗经治局部晚期或转移性三阴性乳腺癌的II期多中心开放标签研究讲者：陶中华（复旦大学附属肿瘤医院）摘要号：4655P 英文标题：Efficacy and Safety of First-Line Treatment for Advanced Triple-Negative Breast Cancer: A Network Meta-Analysis of Randomized Controlled Trials 中文标题：晚期三阴性乳腺癌一线治疗的疗效与安全性：随机对照试验网络荟萃分析讲者：Junxiao Wang (Fuzhou, China) 摘要号：4657P 英文标题：Subtyping-guided addition of bevacizumab to treatment of physician's choice for previously untreated, advanced, basal-like immune-suppressed triple-negative breast cancer (OASIS/BCTOP-T-M01): a randomised, multicentre, phase 3 trial 中文标题：分型指导的贝伐珠单抗联合医生选择方案治疗初治晚期基底样免疫抑制型三阴性乳腺癌（OASIS/BCTOP-T-M01）：一项随机、多中心III期试验讲者：马林晓曦（复旦大学附属肿瘤医院）摘要号：4678P 英文标题：The Efficacy and Safety of Utidelone Plus Tislelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) 中文标题：优替德隆联合替雷利珠单抗和贝伐珠单抗治疗晚期或转移性三阴性乳腺癌（UTILIZABLE研究）讲者：Qingxu Liu (Wuhan, China) 摘要号：4680eP 英文标题：Identification of angiogenesis-related diagnostic and prognostic gene signatures for triple-negative breast cancer via machine learning and single-cell analysis 中文标题：基于机器学习和单细胞分析鉴定三阴性乳腺癌血管生成相关诊断和预后基因特征讲者：Hanbo Wang (Tianjin, China) 摘要号：4682eP 英文标题：Isojacareubin induces apoptosis of chemoresistant-triple negative breast cancer by epigenetic repression of PIK3CA via deacetylation of Histone 3 lysine 56 中文标题：异山竹素通过组蛋白H3K56去乙酰化表观遗传抑制PIK3CA诱导化疗耐药三阴性乳腺癌凋亡讲者：Dar-Ren Chen（中国台湾彰化市）摘要号：4686eP 英文标题：Single-cell transcriptomics reveals drivers of tumor microenvironment reprogramming and immunotherapy resistance in triple-negative breast cancer 中文标题：单细胞转录组学揭示三阴性乳腺癌肿瘤微环境重编程和免疫治疗耐药的驱动因素讲者：Shuangqi Qian (Tianjin, China) 摘要号：4690eP 英文标题：Association of PCSK9 Inhibitor Use With Breast Cancer Survival and Recurrence: A Target Trial Emulation 中文标题：PCSK9抑制剂使用与乳腺癌生存和复发的关联：目标试验模拟讲者：Salida Ali（中国香港）摘要号：4693eP 英文标题：PD-1 Inhibitor Sintilimab Concurrent with Epirubicin, Cyclophosphamide, and Nab-Paclitaxel as Neoadjuvant Therapy for Triple-Negative Breast Cancer: A Single-Arm, Phase II Study 中文标题：PD-1抑制剂信迪利单抗联合表柔比星、环磷酰胺和白蛋白紫杉醇新辅助治疗三阴性乳腺癌：一项单臂II期研究讲者：Duanyang Zhai (Guangzhou, China) 摘要号：4695eP 英文标题：Carboplatin plus taxanes combined with or without PD-1 inhibitors as neoadjuvant therapy in triple-negative breast cancer: A Propensity-Matched Cohort Study 中文标题：卡铂联合紫杉类联合或不联合PD-1抑制剂新辅助治疗三阴性乳腺癌：一项倾向性匹配队列研究讲者：Hongwei Lyu (Beijing, China) 摘要号：4700eP 英文标题：Radiological Complete Response as a Predictor of Neoadjuvant Therapy Efficacy in Early Triple-Negative Breast Cancer: A Multicenter Real-World Study 中文标题：影像学完全缓解作为早期三阴性乳腺癌新辅助治疗疗效的预测因素：一项多中心真实世界研究讲者：Wenyu Yang (Beijing, China) 摘要号：4702eP 英文标题：A Tumor Cell Membrane-Based FTY720 Nanoplatform Synergizes with [177Lu]Lu Radionuclide Therapy for Triple-Negative Breast Cancer 中文标题：基于肿瘤细胞膜的FTY720纳米平台协同[177Lu]Lu放射性核素治疗三阴性乳腺癌讲者：Yuyue Hou (Wuhan, China) 摘要号：4724eP 英文标题：Predictive value of tertiary lymphoid structures for immunotherapy efficacy in triple-negative breast cancer 讲者：三级淋巴结构对三阴性乳腺癌免疫治疗疗效的预测价值讲者：刘月平（河北医科大学第四医院）摘要号：4732eP 英文标题：Landscape of Peripheral Immune Response Induced by Multimodal Thermal Therapy Combined with Chemoimmunotherapy in Patients with Early-stage Triple-negative Breast Cancer 中文标题：多模式热疗联合化学免疫治疗诱导早期三阴性乳腺癌患者外周免疫应答的全景分析讲者：Fei Lin Qu (Shanghai, China) AI for clinical workflows and decision-making（人工智能辅助临床工作流程与决策）摘要号：208P 英文标题：Multimodal Unified Survival Ensemble (MUSE) Predicts Immunotherapy Survival Benefit in Triple-negative Breast Cancer (TNBC): Analysis from the TORCHLIGHT Study 中文标题：多模态统一生存集成模型预测三阴性乳腺癌免疫治疗生存获益：TORCHLIGHT研究分析讲者：江泽飞（解放军总医院） AI for diagnostics and profiling (pathology, radiology, molecular biology)（人工智能辅助诊断与分子分型）摘要号：300P 英文标题：BRIGHT: a breast pathology foundation model for biomarker prediction and treatment stratification in breast cancer 中文标题：BRIGHT：用于乳腺癌生物标志物预测与治疗分层的基础病理模型讲者：刘芳芳（天津医科大学肿瘤医院）摘要号：314P 英文标题：Study on the association between HER2 expression in breast cancer and spatial heterogeneity of microvascular density 中文标题：乳腺癌HER2表达与微血管密度空间异质性的关联研究讲者：Jingyue Li (Shenyang, China) 摘要号：331P 英文标题：An Interpretable Whole-slide Image Framework for Automated Trop-2 H-score Assessment in Breast Cancer 中文标题：可解释的全玻片图像框架用于乳腺癌Trop-2 H-score自动评估讲者：刘月平（河北医科大学第四医院）摘要号：355P 英文标题：A Multimodal Model Integrating Therapeutic Response Patterns and AI-Powered Pathology for Survival Prediction in Breast Cancer After Neoadjuvant Therapy 中文标题：整合治疗反应模式与人工智能病理的多模态模型用于乳腺癌新辅助治疗后生存预测讲者：刘月平（河北医科大学第四医院） Developmental therapeutics（药物研发）摘要号：1119eP 英文标题：Nitazoxanide Induces Ferroptosis in Triple-Negative Breast Cancer by Dual Reprogramming of Iron Metabolism and the β-catenin/GPX4 Axis 中文标题：硝唑尼特通过双重重编程铁代谢和β-catenin/GPX4轴诱导三阴性乳腺癌铁死亡讲者：Tao He (Luzhou, China) Psycho-oncology（心理肿瘤学）摘要号：3495eP 英文标题：Machine Learning Models for Depression Risk Prediction in Breast Cancer Patients: A Cross-Sectional Study Based on the NHANES Database 中文标题：基于NHANES数据库的机器学习模型预测乳腺癌患者抑郁风险：一项横断面研究讲者：Junxiao Wang (Fuzhou, China) Translational research and biomarkers（转化研究与生物标志物）摘要号：4587eP 英文标题：Temperature-Responsive PDDNFs@QDs Integrating Simplified Isolation for Efficient Exosome Analysis Enables Breast Cancer Diagnosis and Subtyping 中文标题：温敏型PDDNFs@QDs整合简化分离实现高效外泌体分析用于乳腺癌诊断与分型讲者：Xiangyue Meng (Chengdu, China) （来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

抗体药物偶联物临床2期临床结果

2026-07-17

·今日头条

#2023全球医药创新成果进展# 2023年全球医药创新成果进展显著。国家药监局批准41个品种（51个品规）创新药上市，获批品规同比2022年上升70%。美国食药监局（FDA）批准127款新药，其中37款新分子实体药涉及36种疾病，像针对乳腺癌就有两款新药获批，美纳里尼的Orserdu是针对特定乳腺

#2023全球医药创新成果进展# 2023年全球医药创新成果进展显著。国家药监局批准41个品种（51个品规）创新药上市，获批品规同比2022年上升70%。美国食药监局（FDA）批准127款新药，其中37款新分子实体药涉及36种疾病，像针对乳腺癌就有两款新药获批，美纳里尼的Orserdu是针对特定乳腺癌患者的新疗法，阿斯利康的Truqap是全球首个获批的AKT抑制剂。欧洲药品管理局批准55款药品上市，数量同比减少43%。值得一提的是，7月百利天恒的双抗ADC伦康依隆妥单抗获批食管鳞癌适应症，它是全球首款获批上市的双抗ADC，为食管鳞癌患者提供新选择，且已开展多项临床试验并获多项突破性疗法认定。

2026-07-17

·良医汇乳腺肿瘤资讯

【1213】从一线标准到耐药破局：全球首个CDK2/4/6抑制剂库莫西利联合氟维司群II期研究（TQB3616-II-04）为CDK4/6i经治人群提供中国方案

整理：肿瘤资讯来源：肿瘤资讯细胞周期蛋白依赖性激酶4/6抑制剂（CDK4/6i）联合内分泌治疗（ET）已成为激素受体阳性、人表皮生长因子受体2阴性（HR+/HER2-）晚期乳腺癌的一线标准方案，但绝大多数患者最终难逃耐药进展，而CDK4/6i经治后二线人群目前尚无公认标准方案，是当前该领域最突出的未尽之需。2026年美国临床肿瘤学会（ASCO）年会上，由辽宁省肿瘤医院孙涛教授与湖南省肿瘤医院欧阳取长教授等共同领衔库莫西利联合氟维司群治疗CDK4/6i经治进展HR+/HER2-晚期乳腺癌的II期研究（Abstract 1082）数据正式公布：研究成功达到主要终点，确认客观缓解率（ORR）达32.4%，10个月无进展生存（PFS）率达61.8%1。作为全球首个口服CDK2/4/6三重靶点抑制剂，库莫西利从耐药机制源头切入，为这一治疗困境人群提供了一种基于机制创新的中国方案。【肿瘤资讯】特邀北京大学肿瘤医院李惠平教授就TQB3616-II-04研究作为观察切入点，结合CDK4/6i经治后的治疗需求与现实困境，探讨HR+/HER2-晚期乳腺癌的治疗发展。李惠平教授主任医师，教授，博士生导师，医学博士北京大学肿瘤医院乳腺肿瘤内科主任美国德克萨斯大学M.D.Anderson学习2年中国女医师协会乳腺专业委员会主任委员中国女医师协会临床肿瘤学专委会副主任委员中国抗癌协会乳腺癌专业委员会常委中国进展期乳腺癌共识指南共同组长和执笔人中华医学会乳腺学组委员Editor of Breast CancerResearch and Treatment 格局演进与复发之忧： CDK4/6i一线标准方案下患者仍难逃进展乳腺癌已成为全球女性发病率最高的恶性肿瘤。根据GLOBOCAN 2022数据，全球每年新发乳腺癌约230万例，中国每年新发约36万例，其中HR+/HER2-亚型约占全部乳腺癌的70%，是临床中最为常见的分子亚型2,3。回顾过去十年， CDK4/6抑制剂联合内分泌治疗深刻重塑了HR+/HER2-晚期乳腺癌的治疗格局。PALOMA-2、MONALEESA-2/7、MONARCH-3及国产创新药物达尔西利的DAWNA-2等一系列关键III期研究一致证实，CDK4/6i联合方案在一线场景中的中位PFS普遍达到23-30个月，较内分泌单药组显著延长，疾病进展或死亡风险降低约42%-49%，由此奠定了“内分泌+CDK4/6i” 作为一线优选方案的循证基石。然而，一线疗效的提升并未改变绝大多数患者最终走向耐药进展的现实。一方面，约20%-30%的HR+/HER2-晚期乳腺癌患者在接受CDK4/6抑制剂联合内分泌一线治疗时即表现为原发耐药；另一方面，30%-40%的初始有效患者会在治疗后2年内出现获得性耐药、疾病再次进展4。尤其值得关注的是，来自MD安德森癌症中心、纳入1826例HR+/HER2-转移性乳腺癌患者的真实世界回顾性研究显示，CDK4/6抑制剂治疗进展后整体后续治疗的中位PFS仅为4.73个月，整体队列中位OS为24.43个月，不同治疗策略（化疗、靶向联合内分泌、单纯内分泌等）之间的PFS无显著差异5。如何为这部分“CDK4/6i经治后”耐药人群提供基于机制创新的高效精准治疗选择，已成为HR+/HER2-晚期乳腺癌领域亟待解决的重要命题。二线求索与标准之困：CDK4/6i经治后人群的选择增多但标准缺位与一线治疗已建立明确标准不同，HR+/HER2-晚期乳腺癌患者在CDK4/6抑制剂经治后进入二线治疗阶段，迄今仍缺乏公认的标准方案。近年来，多项III期研究围绕PAM通路抑制剂（CAPItello-291、VIKTORIA-1等）、CDK4/6i跨线治疗（postMONARCH）以及新型口服SERD（EMERALD、EMBER-3等）展开探索，为临床提供了更多治疗选择。然而，现有方案整体获益仍较有限，多数新型治疗策略的中位PFS仅为5~7个月，且疗效往往依赖于特定分子标志物，如PIK3CA/AKT1/PTEN或ESR1突变。对于缺乏可靶向分子改变，或尚未完成分子检测的患者，治疗选择依然有限，临床仍迫切需要兼具广泛适用性与明确获益的新策略。这一现状也反映在最新指南中。《中国抗癌协会乳腺癌诊治指南与规范（2026精要版）》针对CDK4/6i经治患者列举了依维莫司联合内分泌治疗、卡匹色替联合氟维司群、艾拉司群、更换CDK4/6i、ADC、PARP抑制剂及化疗等多种选择，但大多数方案均受限于特定分子分型、既往治疗史等适用条件，且缺乏头对头研究证据支持优先顺序，反映出该领域仍处于“可选方案丰富、标准路径未定”的发展阶段。 ▲ 《中国抗癌协会乳腺癌诊治指南与规范（2026精要版）》HR+/HER2- MBC治疗推荐跨线之辩与证据之限：CDK4/6i跨线治疗有效但疗效有限，待新的探索在CDK4/6经治后诸多策略中，CDK4/6i跨线治疗（即进展后继续使用原CDK4/6i或换用另一种CDK4/6i），因具有一定的临床可及性而受到广泛关注。但多项前瞻性研究表明，这一策略整体获益有限，疗效亦受具体药物影响。 ▲ CDK4/6i跨线治疗代表性研究汇总对于继续使用原CDK4/6i，PALMIRA和PACE两项II期研究均未证实继续哌柏西利联合内分泌治疗能够改善PFS，提示单纯延续原有CDK4/6i难以克服获得性耐药。相比之下，换用另一种CDK4/6i取得了一定进展。II期MAINTAIN研究首次证实，换用瑞波西利联合内分泌治疗可较单纯更换内分泌治疗显著延长PFS；随后III期postMONARCH研究进一步证实，阿贝西利联合氟维司群亦可带来统计学意义的PFS获益。然而，无论是MAINTAIN还是postMONARCH，中位PFS均仅延长至约5-6个月，临床获益仍相对有限。综合现有证据可见，CDK4/6i跨线治疗虽可为部分患者带来一定获益，但尚不足以从根本上突破耐药瓶颈。要进一步改善CDK4/6i经治患者的长期预后，仅依靠同机制药物轮换已难以满足临床需求，亟需基于耐药生物学机制探索新的治疗策略。机制溯源与原研创新：三重阻断CDK2/4/6，破解耐药困局要破解CDK4/6抑制剂耐药困局，须回到细胞周期调控的分子机制层面。细胞周期G1/S期转换过程中，CDK4/6与Cyclin D结合启动RB蛋白磷酸化；而CDK2与Cyclin E形成复合物后进一步完成RB持续磷酸化，驱动细胞进入DNA复制阶段。基础与临床研究均提示，Cyclin E/CDK2信号轴的代偿性激活，是CDK4/6抑制剂获得性耐药的重要分子机制之一6。也就是说，在CDK4/6持续被抑制后，肿瘤细胞可借助CDK2通路绕过阻断，重新推动细胞增殖。因此，同时覆盖CDK2、CDK4和CDK6，被认为是突破CDK4/6抑制剂耐药的重要方向，也成为当前全球乳腺癌新药研发的核心热点。 ▲ Cyclin E-CDK2通路激活是克服CDK4/6i耐药的潜在靶点库莫西利（TQB3616）正是在这一背景下诞生。作为全球首个获批的口服CDK2/4/6三重靶点抑制剂，库莫西利由中国自主研发并率先完成临床转化。临床前研究显示，库莫西利通过异丙基吲哚母核结构强化了与CDK4靶蛋白的结合，对CDK4具有较强的选择性抑制；同时其与CDK2铰链区形成双氢键，实现对CDK2的高效抑制；而对骨髓造血干细胞中高表达的CDK6呈低选择性抑制，从机制层面提示其可能具有降低严重骨髓抑制风险的潜力7。这一差异化分子设计，奠定了库莫西利在疗效与安全性之间寻求新平衡的理论基础。围绕库莫西利的临床循证体系也已逐步成型。III期CULMINATE-1研究证实，库莫西利联合氟维司群用于内分泌经治HR+/HER2-晚期乳腺癌，将中位PFS延长至16.6个月，疾病进展或死亡风险下降64%（HR=0.36, p<0.0001）；III期CULMINATE-2研究进一步证实其在初治人群中的疗效优势，中位PFS尚未达到，疾病进展或死亡风险降低44%（HR=0.56, p=0.0004），ORR达59.3%8,9。基于上述结果，库莫西利联合氟维司群已先后经NMPA获批二线及一线治疗适应证。然而，对于既往已接受过CDK4/6抑制剂治疗后进展的“耐药”人群，库莫西利能否真正发挥其三重靶点抑制的机制学优势，带来新的临床获益？这正是TQB3616-II-04研究的核心科学命题。机制创新与临床循证：库莫西利为CDK4/6i经治进展人群提供破解耐药新选择 TQB3616-II-04研究（NCT06702618）是一项前瞻性、多中心、单臂II期临床试验，聚焦CDK4/6抑制剂经治进展这一具有较高未满足治疗需求的人群。主要终点为独立评审委员会（IRC）或研究者评估的确认的ORR，次要终点涵盖PFS、临床获益率（CBR）、疾病控制率（DCR）及安全性。截至2026年4月15日，共入组35例患者。整体人群呈现较典型的耐药后疾病特征：中位年龄56岁，71.4%伴内脏转移，肝转移与肺转移比例均接近半数，超过三分之一患者既往接受过化疗。尤其重要的是，所有入组患者既往均接受过CDK4/6i联合内分泌治疗，既往CDK4/6i种类分布广泛：哌柏西利占68.6%、达尔西利占28.6%、瑞波西利占8.6%，其中2例既往接受过两种不同CDK4/6i。这一人群特征高度贴近当前临床实践中复杂且多元的治疗背景，对评价新一代CDK抑制剂“耐药突破”临床价值具有重要现实意义。中位随访10.8个月时，研究达到主要终点。34例可评估患者确认ORR达32.4%（95%CI：17.4-50.5, p<0.0001），显著高于预设阈值；DCR高达88.2%（95% CI: 72.6-96.7），CBR亦达到82.4%（95% CI: 65.5-93.2）；中位至缓解时间（mTTR）为3.7个月。值得关注的是，中位PFS及中位缓解持续时间均尚未达到，10个月PFS率达61.8%（95% CI: 42.3-76.4）。对于既往接受CDK4/6抑制剂治疗失败、且合并高比例内脏转移的患者而言，这一疗效结果提示，库莫西利联合氟维司群显示出显著抗肿瘤活性，并提示其在耐药背景下可能带来较为持久的疾病控制。 ▲ 靶病灶最佳缓解瀑布图 ▲ 无进展生存期（PFS）Kaplan-Meier曲线，中位PFS尚未达到安全性方面，整体表现与既往研究一致，未发现新的安全信号。任何级别治疗相关不良事件（TRAE）发生率为97.1%，≥3 TRAE级为40.0%。值得注意的是，未发生因TRAE导致永久停药，亦无治疗相关死亡。传统CDK4/6抑制剂最受关注的≥3级中性粒细胞减少发生率仅为5.7%，与其低CDK6抑制特征形成良好呼应。整体而言，该方案总体安全性可管理。溯源机制与临床验证：构建HR+/HER2-晚期乳腺癌治疗临床挑战的解决方案 TQB3616-II-04研究的核心临床意义，在于以前瞻性临床证据初步验证：针对CDK4/6抑制剂经治后进展患者，基于CDK2/4/6三重靶点抑制的治疗策略可带来明确的临床获益。从机制上看，库莫西利通过同步阻断Cyclin E/CDK2这一关键耐药旁路，干预细胞周期再激活过程；从临床上看，32.4%的确认ORR、88.2%的DCR及持续获益趋势，使这一机制优势真正转化为初步临床疗效数据。特别值得注意的是，研究纳入患者覆盖不同CDK4/6抑制剂治疗背景，其结果更贴近真实世界临床实践，也提示库莫西利可能具备相对广谱的耐药突破潜力，而非仅局限于特定亚群。同时，研究中超过七成患者伴有内脏转移、近一半患者伴有肝转移、超过三成患者既往已接受过化疗，在这样一组预后较差的难治人群中仍能实现具有临床意义的疾病控制，进一步提示该方案在高危人群中的应用前景。从整体循证布局来看，库莫西利已在晚期一线、二线治疗场景积累关键证据，并开始延展至CDK4/6抑制剂经治进展后人群。随着早期辅助强化III期研究推进，库莫西利有望进一步延伸至乳腺癌全病程治疗管理，为HR+/HER2-乳腺癌构建更加完整的治疗路径。结语与前瞻：中国原创CDK2/4/6抑制剂的耐药破局之路作为全球首个CDK2/4/6三重靶点抑制剂，库莫西利已通过CULMINATE-1与CULMINATE-2两项关键III期研究，确立了其在HR+/HER2-晚期乳腺癌二线及一线治疗中的循证地位，并相继获NMPA批准上市；本次2026 ASCO公布的TQB3616-II-04 研究数据，则将库莫西利的循证版图进一步延展至CDK4/6i经治进展这一未满足需求领域，完成了从“机制创新”到“临床验证”的重要衔接，为长期缺乏标准方案的CDK4/6抑制剂经治后人群提供了重要的循证依据。未来，随着随访成熟及更多生存数据公布，库莫西利联合氟维司群在CDK4/6抑制剂经治后患者中的长期获益将进一步明晰；与此同时，其在早期强化辅助治疗中的研究结果也值得期待。从更宏观的视角看，库莫西利的研发、上市与循证延展，是中国创新药企参与乳腺癌全球核心赛道竞争的“从跟跑到领跑”代表性案例之一。其不仅为中国患者提供了新的治疗选择，亦以“中国研发、全球首创”的姿态，向全球乳腺癌领域贡献了中国循证探索与临床实践经验，为HR+/HER2-乳腺癌治疗策略的持续优化提供了来自中国的重要证据。参考文献 1. Sun T, Ouyang Q, Shi Y, et al. Culmerciclib (CDK2/4/6 inhibitor) plus fulvestrant in HR+/HER2− advanced breast cancer after progression on CDK4/6i: Preliminary results from a phase II trial. 2026 ASCO Annual Meeting, Abstract 1082.2. Kim J, Harper A, McCormack V, et al. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med 2025;31(4):1154-1162. (In eng). DOI: 10.1038/s41591-025-03502-3.3. Fasching PA, Kreipe H, Del Mastro L, et al. Identification of Patients with Early HR+ HER2- Breast Cancer at High Risk of Recurrence. Geburtshilfe Frauenheilkd 2024;84(2):164-184. (In eng). DOI: 10.1055/a-2238-3199.4. Kettner NM, Bui TN, Navarro-Yepes J, et al. IL-6 predicts CDK4/6 inhibitor resistance, identifying STAT3 as a target in HR + /HER2-negative metastatic breast cancer. NPJ Precis Oncol 2025;9(1):260. (In eng). DOI: 10.1038/s41698-025-01041-1.5. Raghavendra AS, Qiao W, Shen Y, Damodaran S, Hunt KK, Tripathy D. Real-world study of treatment patterns and outcomes in patients with HR+ breast cancer after progression on CDK4/6 inhibitor therapy. The Lancet Regional Health – Americas 2026;59. DOI: 10.1016/j.lana.2026.101482.6. Glaviano A, Wander SA, Baird RD, et al. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment. Drug Resistance Updates 2024;76:101103. DOI: https://doi.org/10.1016/j.drup.2024.101103.7. Xu Z, Liu Y, Song B, et al. Discovery and preclinical evaluations of TQB3616, a novel CDK4-biased inhibitor. Bioorg Med Chem Lett 2024;107:129769. (In eng). DOI: 10.1016/j.bmcl.2024.129769.8. Yin Y, Zhang Q, Sun T, et al. Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial. Signal Transduction and Targeted Therapy 2025;10(1):414. DOI: 10.1038/s41392-025-02475-6.9. Song E, Yin Y, Zhao J, et al. LBA25 Culmerciclib plus fulvestrant as first-line treatment for HR+/HER2- advanced breast cancer: A phase III trial (CULMINATE-2). Annals of Oncology 2025;36:S1569-S1570. DOI: 10.1016/j.annonc.2025.09.035. 责任编辑：肿瘤资讯-春明排版编辑：肿瘤资讯-htt 版权声明与免责声明本文专供医学专业人士参考，未经著作人许可，不可出版发行。本文所涉横向研究数据均为非头对头研究比较，仅用于客观循证背景呈现，请谨慎解读；临床决策应严格遵循最新版临床指南、国家药品监督管理局批准的适应证及医师专业判断。

100 项与艾拉司群相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11671	艾拉司群	-	DB06374

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
局部晚期乳腺癌	澳大利亚	A. Menarini Australia Pty Ltd.	2026-04-01
晚期乳腺癌	英国	Stemline Therapeutics, Inc.	2024-01-05
转移性乳腺癌	英国	Stemline Therapeutics, Inc.	2024-01-05
ER阳性/HER2阴性/ESR1突变乳腺癌	美国	Stemline Therapeutics, Inc.	2023-01-27

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
乳腺癌	申请上市	美国	Radius Pharmaceuticals, Inc.	2022-06-22
HR阳性/HER2阴性乳腺癌	临床3期	德国	Berlin-Chemie/Menarini Pharma GmbH	2026-04-29
ER阳性乳腺癌	临床3期	美国	Stemline Therapeutics, Inc.	2024-09-27
ER阳性乳腺癌	临床3期	阿根廷	Stemline Therapeutics, Inc.	2024-09-27
ER阳性乳腺癌	临床3期	澳大利亚	Stemline Therapeutics, Inc.	2024-09-27
ER阳性乳腺癌	临床3期	奥地利	Stemline Therapeutics, Inc.	2024-09-27
ER阳性乳腺癌	临床3期	比利时	Stemline Therapeutics, Inc.	2024-09-27
ER阳性乳腺癌	临床3期	巴西	Stemline Therapeutics, Inc.	2024-09-27
ER阳性乳腺癌	临床3期	加拿大	Stemline Therapeutics, Inc.	2024-09-27
ER阳性乳腺癌	临床3期	捷克	Stemline Therapeutics, Inc.	2024-09-27

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05563220 (ELEVATE, ASCO2026)	临床1/2期	ER阳性/HER2阴性乳腺癌二线 \| 一线 ER+/HER2−	31	CapivasertibElacestrant + CapivasertibElacestrantb	鹽膚構憲範齋艱鹹蓋齋(獵遞壓襯窪醖鬱鏇醖範) = 夢簾簾顧築範膚淵遞壓廠繭襯糧廠獵製艱簾鹹 (醖鏇餘製齋餘夢願醖鑰 ) 更多	积极	2026-05-29
NCT07222215 (CAPELA, ASCO2026)	临床2期	ER阳性乳腺癌 ER positive \| HER2 negative	297	Capecitabine + Elacestrant	鹽壓積獵鑰鏇簾廠衊製(窪願鹹壓鏇壓艱鑰構齋) = 艱積淵選遞醖繭衊簾糧廠夢網餘觸顧鏇廠簾襯 (廠窪簾簾觸簾範淵蓋鹽 )	积极	2026-05-29
				Capecitabine	觸鹹選範膚範遞積築壓(範願構鏇簾構繭窪繭構) = 艱鏇壓夢簾壓鏇鏇鏇製網膚艱願鬱壓顧範夢範 (獵構糧膚鬱廠製獵選獵 ) 更多
NCT06382948 (ADELA, ASCO2026 \| AACR2026)	临床3期	ER阳性/HER2阴性/ESR1突变乳腺癌 ESR1-mutated	240	Elacestrant + Everolimus	膚夢齋積繭淵齋醖鑰艱(膚鏇積壓壓憲遞膚夢鹽) = There was one case (0.5%) of Grade 5 AEs (interruption of CDK4/6i due to increased creatine phosphokinase) with Elacestrant + Everolimus and one case (0.5%) (gastrointestinal bleeding) with Elacestrant + Placebo. 壓齋獵糧網壓網齋蓋憲 (獵築簾願網壓構廠襯鏇 ) 更多	积极	2026-05-29
NCT06492616 (ELEGANT, ASCO2026 \| AACR2026)	临床3期	ER阳性/HER2阴性乳腺癌 ESR1m	4,220	Elacestrant	鑰糧夢遞糧鏇積願鏇鏇(願膚鹹鏇鹽齋鹽衊繭築) = 鏇蓋蓋顧壓網鏇獵襯淵夢獵積鑰繭鹽簾製願艱 (簾顧觸構鬱廠遞鹽齋積 ) 更多	积极	2026-05-29
NCT05982093 (SOLTI-2104 PremiÈRe Part B, ESMO_BC2026)	临床2期	HR阳性/HER2阴性乳腺癌 HR positive \| HER2 negative	48	Elacestrant 345 mg	範鹽鏇築範願糧憲繭觸(蓋鑰構齋網糧繭網選齋) = 選鏇網鏇艱窪簾衊蓋糧襯範鹽艱遞憲窪鏇衊顧 (觸衊壓選艱艱膚蓋醖夢 )	积极	2026-05-07
				Tamoxifen 20 mg	選膚艱夢鏇憲願範艱齋(顧憲選鑰齋鑰願獵憲鬱) = 窪餘選製獵構簾鹹遞鑰餘鹹齋膚膚鬱簾淵製艱 (顧願鏇廠鹽鹹壓夢觸鏇 ) 更多
NCT07159451 (ESMO_BC2026)	临床2期	HR阳性/HER2阴性乳腺癌 HR+ \| HER2-	140	Elacestrant 345 mg	觸淵構蓋艱觸積製顧獵(繭簾淵築鹹醖淵選餘鬱) = 蓋築構遞淵鏇壓襯鏇齋窪鑰獵繭製觸獵鹹製齋 (網壓鏇醖鬱鬱餘獵顧鑰 ) 更多	积极	2026-05-07
				Leuprorelin 3.75 mgElacestrant 345 mg daily + Leuprorelin 3.75 mgElacestrant 345 mg daily (GnRH agonist therapy)	觸鹹築顧糧壓艱夢積壓(簾衊衊齋觸廠餘鹹繭膚) = 觸製顧鹹廠夢衊構糧蓋窪選簾遞憲築廠製遞築 (遞夢遞顧顧襯鏇鹽齋鹽 ) 更多
AACR2026	临床2/3期	HR阳性/HER2阴性乳腺癌 HR Positive \| HER2 Negative	16	Imlunestrant alone	遞醖簾糧窪醖艱製鬱衊(鏇衊積觸鏇醖遞窪願壓) = 鑰夢網繭製膚鬱獵顧觸壓餘鑰製製襯膚選齋顧 (網夢築壓憲鏇壓壓淵遞 ) 更多	积极	2026-04-21
				Camizestrant 75mg	遞醖簾糧窪醖艱製鬱衊(廠襯觸範齋廠簾顧齋襯) = 淵鹽窪鹽觸範鹹蓋範窪淵選淵製範觸鏇衊鏇廠 (願築膚廠鑰簾廠壓膚簾 ) 更多
NCT06492616 (ELEGANT, SABCS2025)	临床3期	ER阳性/HER2阴性乳腺癌 ESR1-mut \| ER+ \| HER2-	4,220	Elacestrant	鑰顧淵艱糧蓋壓憲蓋觸(選築願範襯餘獵壓製鏇) = 獵艱淵遞淵鏇範鹹製鬱築網築膚餘襯糧齋窪廠 (積餘餘鏇廠蓋範衊構襯 )	积极	2025-12-11
SABCS2025	N/A	HR阳性乳腺癌 PIK3CA \| ESR1	107	alpelisib+fulvestrant	觸顧繭襯鹹築淵構齋襯(遞願膚膚範膚醖選鹹蓋) = One patient with alpelisib experienced treatment interruption and dose reduction due to skin toxicity, while Elacestrant was well-tolerated without major adverse effects. 鹽鏇顧獵夢襯鏇範憲蓋 (膚製獵窪製範鹽夢壓襯 )	积极	2025-12-10
				capivasertib+fulvestrant
NCT06382948 (ADELA, SABCS2025)	临床3期	ESR1-mutated \| ER+/HER2-	240	Elacestrant + Everolimus	選製艱遞淵築蓋構膚鹽(鏇鑰簾夢醖夢顧觸襯願) = 鹽憲鑰醖齋觸鏇構餘憲夢繭選廠衊鑰獵鏇醖鹽 (網鬱襯醖糧繭餘餘網糧 )	积极	2025-12-10
				Elacestrant + Placebo	壓願繭夢選構鹹襯淵鹽(鑰齋襯衊襯淵鑰醖淵鹽) = 襯鏇鏇積蓋簾壓鑰選簾膚網餘廠膚繭願選鹽繭 (艱壓餘鬱艱餘餘齋遞顧 )